Price
$93.08+80%1Y
1M-0.27%1Y+80%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageValue84
Quality3
Momentum61
Growth-
What they do
We are a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the phosphatidylinositol 3-kinase (“PI3K”), serine/threonine-protein kinase protein kinase B (“AKT”), mechanistic target of rapamycin (“mTOR”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2.
In the company’s own words · 10-K filed Mar 26, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$4.68B
1Y Return+80%
5Y Return+364%
Raw charts
6 series · TTMAs reported to the SEC, without any scoring.